Oxford Biomedica strikes collaboration agreement with PhoreMost

Oxford Biomedica and PhoreMost hope to develop a next-generation CAR-T cell therapy, with the pharmaceuticals manufacturer deploying its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, to identify therapeutic candidates for Oxford's LentiVector delivery system.

The FTSE 250-listed firm did not disclose any financial details of the agreement.

Chief executive John Dawson said: "We are excited to apply this next-generation technology to our LentiVector platform.

"The collaboration has the potential to deliver more effective CAR-T therapies, and we look forward to working closely with the PhoreMost team."

As of 0915 GMT, Oxford BioMedica shares were up 0.13% at 814.03p.